MINNEAPOLIS, July 1 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today that it was added to the Russell Microcap(R) Index when Russell Investments reconstituted its comprehensive family of U.S. and global equity indexes on June 27, 2008.
Membership in the Russell Microcap, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4.4 trillion in assets currently are benchmarked to them.
"We are pleased with our inclusion in this index, which reflects our continued positive momentum," said David Kaysen, President and CEO. "Russell is an industry leader for stock indexes, and we expect our inclusion will generate greater interest in our stock among investors."
Total returns data for the Russell Microcap and other Russell Indexes is available at http://www.russell.com/Indexes/performance/daily_total_returns_us.asp.
Russell Investments aims to improve financial security for people by providing strategic advice, world-class implementation, state-of-the-art performance benchmarks, and a range of institutional-quality investment products. With more than $213 billion in assets under management, Russell serves individual, institutional and advisor clients in more than 40 countries. Russell provides access to some of the world's best money managers. It helps investors put this access to work in corporate defined benefit and defined contribution plans, and in the life savings of individual investors.
Founded in 1936, Russell is a subsidiary of Northwestern Mutual Life Insurance Company. Headquartered in Tacoma, Wash., U.S., Russell has principal offices in Amsterdam, Auckland, Hong Kong, Johannesburg, London, Melbourne, New York, Paris, San Francisco, Singapore, Sydney, Tokyo and Toronto.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC system, which we believe is the only FDA- approved minimally invasive nerve stimulation device designed for office-based treatment of symptoms often associated with overactive bladder. We also offer Macroplastique(R) Implants, an injectable bulking agent for the treatment of adult female stress urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com.
The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for certain forward-looking statements. This press release contains
forward-looking statements, which reflect our views regarding future events
and financial performance. These forward-looking statements are subject to
certain risks and uncertainties, including those identified below, which
could cause actual results to differ materially from historical results or
those anticipated. The words "aim," "believe," "expect," "anticipate,"
"intend," "estimate" and other expressions, which indicate future events
and trends, identify forward-looking statements. Actual future results and
trends may differ materially from historical results or those anticipated
depending upon a variety of factors, including, but not limited to: the
effect of government regulation, including when and if we receive approval
for marketing products in the United States; the impact of international
currency fluctuations on our cash flows and operating results; the impact
of technological innovation and competition; acceptance of our products by
physicians and patients, our historical reliance on a single product for
most of our current sales; our ability to commercialize our recently
licensed product lines; our intellectual property and the ability to
prevent competitors from infringing our rights; the ability to receive
third party reimbursement for our products; the results of clinical trials;
our continued losses and the possible need to raise additional capital in
the future; our ability to manage our international operations; our ability
to hire and retain key technical and sales personnel; our dependence on key
suppliers; future changes in applicable accounting rules; and volatility in
our stock price. We cannot assure you that inclusion in the Russell
Microcap Index will broaden our investor exposure, or otherwise benefit us
or our stock. We also cannot assure continued inclusion in this Index. We
recommend that you read this press release in conjunction with our Annual
Report on Form 10-K for the fiscal year ended March 31, 2008 on file with
the SEC. Uroplasty undertakes no obligation to update or revise these
forward-looking statements to reflect new events or uncertainties.
For Further Information:
David Kaysen, President and CEO, or
Medi Jiwani, Vice President, CFO, and Treasurer,
Dahlia Bailey (Investors)
|SOURCE Uroplasty, Inc.|
Copyright©2008 PR Newswire.
All rights reserved